KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels

Journal of Neuroscience Methods

Volumn 200, Issue 1, 2011, Pages 54-62

  Zhang, Di ^a   Thimmapaya, Rama ^a   Zhang, Xu Feng ^a   Anderson, David J ^a   Baranowski, John L ^a   Scanio, Marc ^a   Perez Medrano, Arturo ^a   Peddi, Sridhar ^a   Wang, Zhi ^a   Patel, Jyoti R ^a   DeGoey, David A ^a   Gopalakrishnan, Murali ^a   Honore, Prisca ^a   Yao, Betty B ^a   Surowy, Carol S ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Channel modulator; KCNQ; Potassium channel; Selectivity; Thallium influx assay

Indexed keywords

2 (1 ADAMANTYL) N [2,6 DIMETHYL 4 OXO 5 PHENYLTHIENOL[2,3 D]PYRIMIDIN 3(4H) YL]ACETAMIDE; 2 (6 CHLORO PYRIDIN 3 YL) 5,6 DIMETHYL 1H BENZIMIDAZOLE; 5 CHLORO 2 (6 CHLORO PYRIDIN 3 YL) 1H BENZOIMIDAZOLE; 6 CHLORO 2 (6 CHLORO PYRIDIN 3 YL) 5 FLUORO 1H BENZIMIDAZOLE; BENZIMIDAZOLE; ENDO 2 [BICYCLO[3.2.1]OCT 3 YL] N (2 ETHYL 4 OXOQUINAZOLIN 3(4H) YL)ACETAMIDE; EXO 2 BICYCLO[2.2.1]HEPT 2 YL N [2 ISOPROPYL 4 OXOQUINAZOLIN 3(4H) YL]ACETAMIDE; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; POTASSIUM CHANNEL STIMULATING AGENT; QUINAZOLINONE DERIVATIVE; RETIGABINE; THALLIUM; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

CARBAMATES; HEK293 CELLS; HUMANS; ION CHANNEL GATING; KCNQ POTASSIUM CHANNELS; KCNQ2 POTASSIUM CHANNEL; KCNQ3 POTASSIUM CHANNEL; MUTATION; PHENYLENEDIAMINES; THALLIUM;

EID: 79960892980     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2011.06.014     Document Type: Article

References (40)

1. Biervert C., Schroeder B.C., Kubisch C., Berkovic S.F., Propping P., Jentsch T.J., et al. A potassium channel mutation in neonatal human epilepsy. Science 1998, 279:403-406.
2. Blackburn-Munro G., Dalby-Brown W., Mirza N.R., Mikkelsen J.D., Blackburn-Munro R.E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005, 11:1-20.
3. Blackburn-Munro G., Jensen B.S. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003, 460:109-116.
4. Brown D.A., Adams P.R. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 1980, 283:673-676.
5. Brown D.A., Passmore G.M. Neural KCNQ (Kv7) channels. Br J Pharmacol 2009, 156:1185-1195.
6. Brueggemann L.I., Mackie A.R., Martin J.L., Cribbs L.L., Byron K.L. Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits. Mol Pharmacol 2011, 79:10-23.
7. Charlier C., Singh N.A., Ryan S.G., Lewis T.B., Reus B.E., Leach R.J., et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998, 18:53-55.
8. Dalby-Brown W., Hansen H.H., Korsgaard M.P., Mirza N., Olesen S.P. K(v)7 channels: function, pharmacology and channel modulators. Curr Top Med Chem 2006, 6:999-1023.
9. Delmas P., Brown D.A. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 2005, 6:850-862.
10. Friedel H.A., Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993, 45:548-569.
11. Gao Z., Zhang T., Wu M., Xiong Q., Sun H., Zhang Y., et al. Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem 2010, 285:28322-28332.
12. Hadley J.K., Passmore G.M., Tatulian L., Al-Qatari M., Ye F., Wickenden A.D., et al. Stoichiometry of expressed KCNQ2/KCNQ3 potassium channels and subunit composition of native ganglionic M channels deduced from block by tetraethylammonium. J Neurosci 2003, 23:5012-5019.
13. Hansen H.H., Ebbesen C., Mathiesen C., Weikop P., Ronn L.C., Waroux O., et al. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. J Pharmacol Exp Ther 2006, 318:1006-1019.
14. Hansen H.H., Waroux O., Seutin V., Jentsch T.J., Aznar S., Mikkelsen J.D. Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS. J Physiol 2008, 586:1823-1832.
15. Jentsch T.J. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 2000, 1:21-30.
16. Kharkovets T., Hardelin J.P., Safieddine S., Schweizer M., El-Amraoui A., Petit C., et al. KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci U S A 2000, 97:4333-4338.
17. Klawe C., Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother 2009, 10:1495-1500.
18. Lange W., Geissendorfer J., Schenzer A., Grotzinger J., Seebohm G., Friedrich T., et al. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 2009, 75:272-280.
19. Mackie A.R., Byron K.L. Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. Mol Pharmacol 2008, 74:1171-1179.
20. Maljevic S., Wuttke T.V., Lerche H. Nervous system KV7 disorders: breakdown of a subthreshold brake. J Physiol 2008, 586:1791-1801.
21. Munro G., Dalby-Brown W. Kv7 (KCNQ) channel modulators and neuropathic pain. J Med Chem 2007, 50:2576-2582.
22. Padilla K., Wickenden A.D., Gerlach A.C., McCormack K. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett 2009, 465:138-142.
23. Passmore G.M., Selyanko A.A., Mistry M., Al-Qatari M., Marsh S.J., Matthews E.A., et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 2003, 23:7227-7236.
24. Porter R.J., Partiot A., Sachdeo R., Nohria V., Alves W.M. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007, 68:1197-1204.
25. Robbins J. KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacol Ther 2001, 90:1-19.
26. Rostock A., Tober C., Rundfeldt C., Bartsch R., Engel J., Polymeropoulos E.E., et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996, 23:211-223.
27. Scanio MJ, Bunnelle WH, Carroll WA, Peddi S, Perez-Medrano A, Shi L. Potassium channel modulators. Patent WO2010138828 A2; 2010.
28. Schenzer A., Friedrich T., Pusch M., Saftig P., Jentsch T.J., Grotzinger J., et al. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 2005, 25:5051-5060.
29. Schroeder B.C., Hechenberger M., Weinreich F., Kubisch C., Jentsch T.J. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 2000, 275:24089-24095.
30. Selyanko A.A., Sim J.A. Ca2+-inhibited non-inactivating K+ channels in cultured rat hippocampal pyramidal neurones. J Physiol 1998, 510:71-91.
31. Singh N.A., Charlier C., Stauffer D., DuPont B.R., Leach R.J., Melis R., et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998, 18:25-29.
32. Tatulian L., Delmas P., Abogadie F.C., Brown D.A. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001, 21:5535-5545.
33. Wang H.S., Pan Z., Shi W., Brown B.S., Wymore R.S., Cohen I.S., et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998, 282:1890-1893.
34. Watanabe H., Nagata E., Kosakai A., Nakamura M., Yokoyama M., Tanaka K., et al. Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J Neurochem 2000, 75:28-33.
35. Weaver C.D., Harden D., Dworetzky S.I., Robertson B., Knox R.J. A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J Biomol Screen 2004, 9:671-677.
36. Wei A.D., Butler A., Salkoff L. KCNQ-like potassium channels in Caenorhabditis elegans. Conserved properties and modulation. J Biol Chem 2005, 280:21337-21345.
37. Wickenden A.D., Krajewski J.L., London B., Wagoner P.K., Wilson W.A., Clark S., et al. N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol Pharmacol 2008, 73:977-986.
38. Wickenden A.D., Roeloffs R., McNaughton-Smith G., Rigdon G.C. KCNQ potassium channels: drug targets for the treatment of epilepsy and pain. Expert Opin Ther Patents 2004, 14:457-469.
39. Wickenden A.D., Zou A., Wagoner P.K., Jegla T. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001, 132:381-384.
40. Wuttke T.V., Seebohm G., Bail S., Maljevic S., Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005, 67:1009-1017.